
    
      This is an open-label (volunteers will know the names of treatments they are assigned)
      single-center and cross-over study of SP2086 and Valsartan in healthy adult volunteers. All
      subject were randomized into two groups, and the drugs will be administered according to the
      AB and BA sequences, all subjects must completed the two stages(A and B). The A sequence was
      that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by
      mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on
      Days 8-Day12.There were 6 days washout period between the two stages. The whole study needs
      31 days.
    
  